Literature Review: Branch Site Mutated Mice Reveal Distinct Roles of Two Runx2 Isotypes in Skeletal Development

Literature Review: Branch Site Mutated Mice Reveal Distinct Roles of Two Runx2 Isotypes in Skeletal Development

1. Publication Overview

• Title: Branch site mutated mice revealed distinct roles of two Runx2 isoforms

• Journal: Frontiers in Cell and Developmental Biology, 2026 (JCR Q1, latest IF = 5.3, SCI-indexed open access journal)

• DOI: 10.3389/fcell.2026.1770176

2. Core Conclusions

The study constructs a novel Runx2 branch splice site mutant mouse (Runx2-brmut/mut) that precisely separates the in vivo functions of the two Runx2 isoforms, Runx2-I and Runx2-II. Runx2-II governs osteoblast differentiation and skeletal mineralisation, whereas Runx2-I specifically regulates the proliferation of cranial suture mesenchymal cells, providing compensatory protection for calvarial and clavicular development. The two isoforms are functionally complementary, but Runx2-I cannot fully compensate for the osteogenic defects caused by the absence of Runx2-II. The study further demonstrates that Runx2 is not subject to autoregulatory transcriptional feedback and that the P1/P2 dual promoters engage in competitive transcriptional interaction, providing a new molecular mechanism and therapeutic target for cleidocranial dysplasia (CCD), osteoporosis and related disorders of bone metabolism.

3. Role of Absin Products in the Study

The study used the Absin Fast Red Violet LB salt (catalogue number abs42018403) for TRAP (tartrate-resistant acid phosphatase) tissue staining. This chromogenic substrate specifically labels osteoclasts within bone tissue, allowing the quantitative assessment of osteoclast numbers in mutant mice and revealing the indirect regulatory effect of Runx2 isoform imbalance on osteoclastogenesis. The reagent guarantees clear enzymatic activity staining with low background on bone sections, providing standardised support for skeletal histology quantification.

4. Background

Runx2 is the core transcription factor controlling vertebrate skeletal development, directly regulating osteoblast differentiation, chondrocyte maturation and the transdifferentiation of hypertrophic chondrocytes into osteoblasts. Heterozygous mutations of human RUNX2 cause cleidocranial dysplasia syndrome (CCD), and Runx2+/− mice reproduce the skeletal malformation phenotype of CCD. Runx2 exists as two functional isoforms: the distal P1 promoter transcribes Runx2-II and the proximal P2 promoter transcribes Runx2-I. The two isoforms differ in their N-terminal amino acid sequence while sharing the core Runt DNA-binding domain.

Previous Runx2-II knockout models (Runx2-II−/− and Runx2-II^lacZ/lacZ) produced contradictory skeletal phenotypes, and no mature Runx2-I-specific knockout animal model was available. The isoform-specific physiological functions in intramembranous ossification, endochondral ossification and osteoclast balance therefore remained controversial, and direct in vivo evidence was lacking for Runx2 dual promoter transcriptional regulation, for compensation between isoforms and for autoregulatory feedback.

To address these gaps, the study introduces a splice branch site mutant mouse that selectively suppresses mature Runx2-II mRNA synthesis while upregulating Runx2-I expression, thereby separating the two isoforms in vivo while retaining their complete genomic context, and systematically resolves their differentiated roles in embryonic, neonatal and adult skeletal development.

5. Overall Study Design

The work follows a nine-level logical chain: construction of a novel animal model, verification of isoform expression, whole-embryo skeletal phenotype analysis, histological analysis of cartilage, osteogenesis and osteoclast balance, comparison of neonatal calvarial and clavicular phenotypes against the classic CCD model, assessment of adult bone microarchitecture and biomechanics at eight weeks, in vitro validation of mesenchymal and primary osteoblast differentiation, and analysis of the transcriptional regulatory mechanism.

1. CRISPR-Cas9 gene editing generated Runx2-brmut/mut branch site mutant mice, with genotype, survival rate and splicing abnormality characterised.

2. qPCR, droplet digital PCR and western blotting confirmed marked down-regulation of Runx2-II and compensatory elevation of Runx2-I in the mutant.

3. Whole-skeleton Alizarin red and Alcian blue staining of E15.5 embryos compared the extent of delay in intramembranous and endochondral mineralisation.

4. Femoral H&E, Safranin O and TRAP staining (Absin Fast Red Violet LB salt) analysed cartilage maturation, primary trabecular formation and osteoclast numbers.

5. Parallel comparison with the classic CCD model Runx2+/− in neonates localised the calvarial protective function of Runx2-I.

6. Micro-CT, dynamic bone histomorphometry and three-point bending tests at eight weeks evaluated long-term bone mass and skeletal strength.

7. Osteogenic marker gene quantification combined with in vitro induction of BMSCs and primary osteoblasts demonstrated that Runx2-II is essential for osteogenic differentiation.

8. EdU proliferation staining confirmed that Runx2-I specifically promotes cranial suture mesenchymal proliferation, explaining the milder calvarial malformation.

9. Overexpression and knockdown together with a P2 promoter luciferase reporter excluded Runx2 autoregulatory feedback and proposed a model of competitive P1/P2 promoter regulation.

6. Module-by-Module Analysis

6.1 Construction of the branch site mutant model and isoform expression profiling

Logic: a point mutation was targeted at the Intron1 splice branch site to disrupt normal Exon1–Exon2 splicing, selectively reducing Runx2-II while monitoring the change in Runx2-I expression, thereby generating a stable model of isoform imbalance.

Core experiments: CRISPR-Cas9 gene editing; genotyping by sequencing; cDNA agarose gel electrophoresis; RT-qPCR; droplet digital PCR; western blotting.

Key results:

• After the CGCTAAC branch site was mutated to ACAGTTG, Exon1 aberrantly spliced to Exon3, generating a truncated, non-functional Runx2-II transcript.

• Runx2-II mRNA was markedly reduced in E15.5 limbs, neonatal calvaria and 8-week tibiae of Runx2-brmut/mut mice, with compensatory elevation of Runx2-I. In wild-type embryos, Runx2-II expression was three times that of Runx2-I.

• Approximately 20% of homozygous mutant mice died after birth, and surviving individuals showed lower body weight throughout the growth period.

6.2 Embryonic skeletal mineralisation and femoral histology, including the Absin TRAP staining experiment

Logic: overall skeletal development was assessed at the embryonic stage, using histological staining to monitor cartilage maturation, osteogenesis and changes in osteoclast numbers.

Core experiments: whole-skeleton Alizarin red and Alcian blue staining of E15.5 embryos; paraffin sections of femur stained with H&E and Safranin O; TRAP osteoclast staining using Absin Fast Red Violet LB salt; qPCR of cartilage and osteogenic markers.

Use of the Absin product: for TRAP staining of bone sections, Absin Fast Red Violet LB salt (abs42018403) was used as the chromogenic substrate. It couples with the hydrolysis product of the osteoclast marker enzyme tartrate-resistant acid phosphatase to generate a specific purple-red signal, allowing TRAP-positive osteoclasts to be counted under the microscope.

Key results:

• The mineralised area of calvaria, clavicles, scapulae and hip bones was significantly reduced in Runx2-brmut/mut embryos, indicating delayed intramembranous ossification.

• The hypertrophic zone of the femur was expanded and primary trabecular formation was impaired, with up-regulation of the cartilage maturation markers Sox9 and Col2a1, indicating arrested endochondral ossification.

• TRAP quantification showed a significant reduction in the number of TRAP-positive osteoclasts in the bone marrow of mutant mice, demonstrating that the loss of Runx2-II indirectly suppresses osteoclastogenesis.

6.3 Comparison of neonatal phenotypes against the CCD model Runx2+/−

Logic: two CCD-related models were compared in parallel to distinguish the skeletal malformations caused by reduced total Runx2 from those caused by specific loss of Runx2-II, and to uncover the calvarial protective function of Runx2-I.

Core experiments: whole-skeleton staining of neonatal mice; quantification of cranial sutures, clavicles and limb bones.

Key results:

• Both models exhibited an unclosed anterior fontanelle and absent nasal bone mineralisation, but the clavicular defect of Runx2-brmut/mut was far milder than that of Runx2+/−.

• The degree of endochondral ossification arrest in the limbs was greater in Runx2+/− than in Runx2-brmut/mut, demonstrating that the upregulated Runx2-I partially compensates for the endochondral ossification defect.

6.4 Bone microarchitecture, dynamic histomorphometry and mechanical testing in eight-week-old adults

Logic: the long-term defects of bone metabolism were evaluated, defining the sustained impairment of bone mass, bone formation rate and skeletal strength caused by the loss of Runx2-II.

Core experiments: Micro-CT of femoral microarchitecture; calcein double-labelling dynamic bone histomorphometry; three-point bending biomechanical testing of the humerus.

Key results:

• Trabecular bone volume, bone mineral density and cortical thickness were all significantly reduced in mutant mice, with a comprehensive decrease in bone formation rate (MAR, BFR/BS).

• Maximum load and stiffness of the humerus declined, indicating compromised mechanical strength. The adult bone defect was significantly more severe than in the classic Runx2+/− model, establishing that Runx2-II is required to sustain adult osteogenesis.

6.5 Cranial suture mesenchymal proliferation as the basis of the compensatory mechanism

Logic: this module addresses why calvarial malformation is milder in the mutant than in Runx2+/−, testing the isoform-specific proliferative function of Runx2-I.

Core experiments: EdU proliferation staining in P7 pups; separate quantification of proliferation in cranial suture mesenchyme, growth plate cartilage and trabecular osteoblasts.

Key results:

• The number of EdU-positive proliferating cells in the sagittal cranial suture was significantly increased in Runx2-brmut/mut mice.

• No difference was observed in the proliferation of growth plate chondrocytes or trabecular osteoblasts, confirming that Runx2-I specifically promotes cranial suture mesenchymal proliferation and thereby compensates for the calvarial development defect caused by the loss of Runx2-II.

6.6 In vitro differentiation of BMSCs and primary osteoblasts

Logic: the cellular level directly demonstrates that Runx2-II is the key isoform for osteoblast lineage differentiation.

Core experiments: osteogenic induction of bone marrow mesenchymal stem cells (BMSCs) and primary osteoblasts (POB); ALP staining; Von Kossa mineralisation staining; qPCR of osteogenic marker genes.

Key results:

• ALP activity and mineralised nodules were almost absent in BMSCs from Runx2-brmut/mut mice, and core osteogenic genes such as Sp7 and Bglap were strongly down-regulated.

• Maturation of primary osteoblasts likewise depended on Runx2-II, and Runx2-I alone was insufficient to support complete osteogenic differentiation.

6.7 Transcriptional self-regulation mechanism

Logic: the module tests whether the elevation of Runx2-I in the mutant is mediated by negative autoregulation of Runx2 protein, and resolves the regulatory mode of the P1/P2 dual promoters.

Core experiments: Runx2 overexpression and siRNA knockdown in MC3T3-E1 cells; P2 promoter luciferase reporter assay.

Key results:

• Exogenous Runx2 overexpression did not alter endogenous Runx2-I or Runx2-II levels, and Runx2 knockdown did not affect P2 promoter activity.

• Runx2 is therefore not subject to autoregulatory feedback, and the increased Runx2-I in the mutant arises from competitive binding of the P1 and P2 promoters to shared enhancers.

7. Overall Contribution of the Absin Product

1. Core chromogenic reagent for osteoclast-specific labelling. All bone TRAP staining in this study used Absin Fast Red Violet LB salt (abs42018403). It couples with the hydrolysis product of the osteoclast marker enzyme TRAP to generate a stable purple-red precipitate, clearly distinguishing multinucleated osteoclasts from other bone cells, with clean section background and strong staining specificity, permitting precise quantification of the reduction in osteoclast numbers in Runx2-brmut/mut mice.

2. Standardised support for quantitative skeletal pathology. The reagent is applicable to paraffin sections of femur from embryonic, neonatal and adult mice, providing a unified staining system that allows osteoclast phenotypes to be compared horizontally across developmental stages and supplies direct histological evidence for the regulation of bone remodelling balance by Runx2 isoform imbalance.

3. Compliant histological tool for high-impact journal data. The staining stability and reproducibility of the reagent satisfy the image quantification requirements of Frontiers in Cell and Developmental Biology, and the TRAP results serve as key phenotypic corroboration supporting the central inference that the loss of Runx2-II suppresses both osteogenesis and osteoclastogenesis, making it an indispensable chromogenic substrate for skeletal developmental histology.

Contact Absin

Absin provides antibodies, proteins, ELISA kits, cell culture, detection kits, and other research reagents. If you have any product needs, please contact us.

Absin Bioscience Inc. worldwide@absin.cn

Follow us on Facebook: Absin Bio